Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0020438 (
hypercalciuria
)
2,502
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The greatest risk factor for kidney stones is
hypercalciuria
, the etiology of which is largely unknown. A recent genome-wide association study (GWAS) linked
hypercalciuria
and kidney stones to a claudin-14 (CLDN14) risk haplotype. However, the underlying molecular mechanism was not delineated. Recently, renal CLDN14 expression was found to increase in response to increased plasma calcium, thereby inducing calciuria. We hypothesized therefore that some children with
hypercalciuria
and kidney stones harbor a CLDN14 variant that inappropriately increases gene expression. To test this hypothesis, we sequenced the CLDN14 risk haplotype in a cohort of children with idiopathic
hypercalciuria
and kidney stones. An intronic SNP was more frequent in affected children. Dual luciferase and cell-based assays demonstrated increased reporter or CLDN14 expression when this polymorphism was introduced. In silico studies predicted the SNP introduced a novel
insulinoma-associated 1
(
INSM1
) transcription factor binding site. Consistent with this, repeating the dual luciferase assay in the presence of
INSM1
further increased reporter expression. Our data suggest that children with the
INSM1
binding site within the CLDN14 risk haplotype have a higher likelihood of
hypercalciuria
and kidney stones. Enhanced CLDN14 expression may play a role in the pathophysiology of their
hypercalciuria
.
...
PMID:A variant in a cis-regulatory element enhances claudin-14 expression and is associated with pediatric-onset hypercalciuria and kidney stones. 2822 5